AI Portfolio Summary
In 2019 Q1, BB BIOTECH AG maintained a portfolio of 36 distinct positions. The most significant new addition to the portfolio was Crispr Therapeutics , which now represents 0.73% of the total fund value. They heavily accumulated shares in Neurocrine Bioscienc, increasing their position by 0.7%. Conversely, BB BIOTECH AG completely exited their position in Regeneron Pharmaceut.
Total Positions
36
Quarter
2019 Q1
Top Holding
IONS (15.8%)
Top 10 Concentration
64.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-36 of 36
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceu...
|
Healthcare | 15.76% | 15.14% |
#1
Prev: #1
|
6.5 | -1,016,334 | -11.6% |
P
S
|
7,725,000 | $627,038,000 | 2010 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
INCY
Incyte Corp.
|
Healthcare | 7.83% | 7.76% |
#2
Prev: #2
|
5.1 | -188,322 | -4.9% |
P
S
|
3,620,000 | $311,356,000 | 2004 Q3 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
NBIX
Neurocrine Bios...
|
Healthcare | 7.46% | 7.65% |
#3
Prev: #3
|
4.5 | 23,696 | 0.7% |
P
S
|
3,366,786 | $296,614,000 | 2000 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
VRTX
Vertex Pharmace...
|
Healthcare | 6.01% | 7.28% |
#4
Prev: #4
|
3.4 | -70,445 | -5.1% |
P
S
|
1,300,000 | $239,135,000 | 1999 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
SAGE
Sage Therapeuti...
|
Unknown | 5.50% | 4.22% |
#5
3
Prev: #8
|
3.7 | no change | no change |
P
S
|
1,375,229 | $218,730,000 | 2015 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
CELG
Celgene Corp
|
Unknown | 5.22% | 4.73% |
#6
Prev: #6
|
2.6 | -103,875 | -4.5% |
P
S
|
2,200,000 | $207,548,000 | 2000 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
AGIO
Agios Pharmaceu...
|
Healthcare | 5.05% | 4.25% |
#7
Prev: #7
|
2.5 | 100,000 | 3.5% |
P
S
|
2,978,134 | $200,845,000 | 2014 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
ALXN
Alexion Pharmac...
|
Unknown | 4.47% | 4.10% |
#8
1
Prev: #9
|
2.8 | no change | no change |
P
S
|
1,314,428 | $177,684,000 | 1999 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
ALNY
Alnylam Pharmac...
|
Healthcare | 3.83% | 3.67% |
#9
2
Prev: #11
|
2.0 | 59,700 | 3.8% |
P
S
|
1,631,089 | $152,425,000 | 2013 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
ESPR
Esperion Therap...
|
Healthcare | 3.56% | 5.00% |
#10
5
Prev: #5
|
1.9 | 130,000 | 3.8% |
P
S
|
3,522,964 | $141,447,000 | 2015 Q3 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
RDUS
Radius Health, ...
|
Unknown | 3.40% | 3.54% |
#11
1
Prev: #12
|
1.9 | 71,409 | 1.1% |
P
S
|
6,781,685 | $135,227,000 | 2014 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
HALO
Halozyme Therap...
|
Healthcare | 3.37% | 3.90% |
#12
2
Prev: #10
|
2.3 | no change | no change |
P
S
|
8,322,860 | $133,998,000 | 2010 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
ARGX
Argenx SE
|
Healthcare | 2.84% | 2.72% |
#13
Prev: #13
|
1.6 | 20,000 | 2.3% |
P
S
|
904,739 | $112,948,000 | 2018 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
MRNA
Moderna, Inc.
|
Healthcare | 2.45% | 2.34% |
#14
1
Prev: #15
|
2.0 | no change | no change |
P
S
|
4,785,681 | $97,389,000 | 2018 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
N/A
Myovant Science...
|
—
|
Unknown | 2.16% | 1.89% |
#15
3
Prev: #18
|
1.9 | no change | no change |
P
S
|
3,597,882 | $85,881,000 | — | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | ||
|
ICPT
Intercept Pharm...
|
Unknown | 1.96% | 1.86% |
#16
3
Prev: #19
|
3.3 | 121,257 | 21.1% |
P
S
|
696,976 | $77,964,000 | 2015 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
GILD
Gilead Sciences...
|
Healthcare | 1.87% | 2.67% |
#17
3
Prev: #14
|
1.2 | -190,000 | -14.3% |
P
S
|
1,142,204 | $74,255,000 | 2003 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
NKTR
Nektar Therapeu...
|
Healthcare | 1.71% | 1.45% |
#18
3
Prev: #21
|
3.2 | 639,701 | 46.3% |
P
S
|
2,020,676 | $67,895,000 | 2018 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
EXEL
Exelixis, Inc.
|
Healthcare | 1.70% | 1.79% |
#19
1
Prev: #20
|
1.7 | no change | no change |
P
S
|
2,835,000 | $67,473,000 | 2018 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
AKCA
Akcea Therapeut...
|
Unknown | 1.69% | 2.30% |
#20
4
Prev: #16
|
1.2 | -8,833 | -0.4% |
P
S
|
2,377,638 | $67,358,000 | 2017 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
MYOK
Myokardia Inc.
|
Unknown | 1.65% | 1.37% |
#21
1
Prev: #22
|
3.2 | 387,647 | 44.2% |
P
S
|
1,264,913 | $65,763,000 | 2018 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
MGNX
MacroGenics Inc...
|
Healthcare | 1.54% | 1.34% |
#22
1
Prev: #23
|
1.1 | 116,728 | 3.6% |
P
S
|
3,400,000 | $61,132,000 | 2016 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
WVE
Wave Life Scien...
|
Healthcare | 1.43% | 1.97% |
#23
6
Prev: #17
|
1.6 | no change | no change |
P
S
|
1,465,002 | $56,915,000 | 2017 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
VYGR
Voyager Therape...
|
Healthcare | 1.38% | 0.86% |
#24
2
Prev: #26
|
1.6 | no change | no change |
P
S
|
2,865,841 | $54,852,000 | 2017 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
BOLD
Audentes Therap...
|
Healthcare | 1.34% | 0.53% |
#25
5
Prev: #30
|
3.5 | 600,200 | 78.0% |
P
S
|
1,369,604 | $53,442,000 | 2018 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
ALDR
Alder Biopharma...
|
Unknown | 0.95% | 0.91% |
#26
1
Prev: #25
|
1.4 | no change | no change |
P
S
|
2,766,008 | $37,756,000 | 2015 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
CRSP
Crispr Therapeu...
|
Healthcare | 0.73% | — |
#27
Prev: #—
|
3.8 | 810,462 | no change |
NEW
|
810,462 | $28,950,000 | 2019 Q1 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
SRRK
Scholar Rock Ho...
|
Healthcare | 0.70% | 0.94% |
#28
4
Prev: #24
|
2.3 | 196,861 | 15.4% |
P
S
|
1,476,839 | $27,750,000 | 2018 Q3 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
ITCI
Intra-Cellular ...
|
Unknown | 0.67% | 0.80% |
#29
1
Prev: #28
|
1.3 | no change | no change |
P
S
|
2,200,000 | $26,796,000 | 2016 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
SGMO
Sangamo Therape...
|
Healthcare | 0.64% | 0.50% |
#30
1
Prev: #31
|
3.3 | 1,300,000 | 96.3% |
P
S
|
2,650,000 | $25,281,000 | 2018 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
KZR
Kezar Life Scie...
|
Healthcare | 0.54% | 0.62% |
#31
2
Prev: #29
|
2.7 | 402,071 | 49.1% |
P
S
|
1,220,503 | $21,652,000 | 2018 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
GTHX
G1 Therapeutics...
|
Unknown | 0.28% | 0.41% |
#32
1
Prev: #33
|
1.1 | no change | no change |
P
S
|
671,925 | $11,154,000 | 2018 Q2 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
N/A
Cidara Therapeu...
|
—
|
Unknown | 0.15% | 0.17% |
#33
1
Prev: #34
|
1.1 | no change | no change |
P
S
|
2,295,272 | $6,082,000 | — | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | ||
|
NVAX
Novavax Inc.
|
Healthcare | 0.12% | 0.49% |
#34
2
Prev: #32
|
1.0 | no change | no change |
P
S
|
8,330,000 | $4,589,000 | 2014 Q3 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | |||
|
N/A
Homology Medici...
|
—
|
Unknown | 0.06% | — |
#35
Prev: #—
|
3.5 | 91,336 | no change |
NEW
|
91,336 | $2,533,000 | — | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) | ||
|
REGN
Regeneron Pharm...
|
Healthcare | 0.00% | 0.82% |
Sold All 😨
(Was: #27) |
0.0 | -68,156 | -100.0% |
CLOSED
|
— | $— | 2001 Q4 | 13F Filing | 2019-03-31 | 2019-05-15 (Est.) |
Showing 1-36 of 36 holdings